Ember LifeSciences Secures $16.5M Series A to Disrupt Global Cold Chain, Cut $35B in Waste
Ember LifeSciences, Inc., a pioneer in advanced temperature control technology, today announced the close of a $16.5 million Series A funding round. The investment is earmarked to rapidly advance the company’s mission of redefining global medicine distribution, an industry segment currently plagued by approximately $35 billion in annual financial losses due to temperature excursions. The…